Clinical Trials Logo

Clinical Trial Summary

Primary Objective: - To describe the clinical characteristics of participants with chronic rhinosinusitis with nasal polyps (CRSwNP) in terms of disease severity, Type 2 inflammation-related comorbidities (such as asthma and allergic rhinitis), other associated comorbidities, and treatments used in a real-world setting Secondary Objectives: - Describe the progression in treatment outcomes at different visits (baseline, 3 months, 6 months, and 12 months). - To assess the healthcare resource utilization of participants with CRSwNP in countries of the Gulf region (number of visits, emergency room (ER), surgery, etc).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05649813
Study type Observational [Patient Registry]
Source Sanofi
Contact Trial Transparency email recommended (Toll free for US & Canada)
Phone 800-633-1610
Email Contact-US@sanofi.com
Status Recruiting
Phase
Start date November 20, 2022
Completion date May 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05895929 - The Role of IL5 in Epithelial Cell Integrity Early Phase 1
Recruiting NCT05891483 - Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps Phase 2
Recruiting NCT04998604 - EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients Phase 4
Recruiting NCT06069310 - Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
Recruiting NCT05009758 - Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps N/A
Active, not recruiting NCT05529784 - Dupilumab in the Treatment of Severe Uncontrolled CRSwNP: a Multicentre Observational Real-life Study (DUPIREAL)
Recruiting NCT05902325 - Identifying Predictors Of Response To Mepolizumab In CRSwNP Phase 4
Completed NCT05049122 - Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52) Phase 4
Not yet recruiting NCT05598411 - CST1-Guided Oral Glucocorticoids Management for CRSwNP Phase 4
Active, not recruiting NCT05553951 - Adherence in Global Airways N/A
Recruiting NCT05131464 - The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps Phase 2
Recruiting NCT05598424 - CST1 Predictive Model of Oral Glucocorticoid Therapy Sensitivity for Chronic Rhinosinusitis With Polyps Phase 4
Recruiting NCT04628442 - Tissue Immune Interaction in Nasal Polyposis
Active, not recruiting NCT06118554 - 3D Printing to Improve Nasal Irrigation Outcome N/A
Recruiting NCT04596189 - Dupilumab for Prevention of Recurrence of CRSwNP After ESS Phase 4
Recruiting NCT02668861 - Effect of Oral Vitamin D3 on Chronic Rhinosinusitis Treatment in Adults With Lower Vitamin D Levels Phase 3
Recruiting NCT05878093 - Dupilumab in Chinese Adult Participants With CRSwNP Phase 3
Completed NCT05931744 - The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis Phase 2/Phase 3
Recruiting NCT05938972 - Real Life Study of Biologicals in Patients With Severe CRSwNP
Not yet recruiting NCT05157412 - Role of Doxycycline in Chronic Rhinosinusitis With Nasal Polyps Phase 3